Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

BPTH

Bio Path (BPTH)

Bio Path Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BPTH
DateTimeSourceHeadlineSymbolCompany
05/24/20246:00AMGlobeNewswire Inc.Bio-Path Holdings to Present Data at 2024 European Hematology Association CongressNASDAQ:BPTHBio Path Holdings Inc
05/23/20244:00PMGlobeNewswire Inc.Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:BPTHBio Path Holdings Inc
05/15/20246:50AMIH Market NewsU.S. Index Futures Flat Ahead of April CPI Data Release, Oil Prices DropNASDAQ:BPTHBio Path Holdings Inc
05/15/20246:10AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BPTHBio Path Holdings Inc
05/15/20246:00AMGlobeNewswire Inc.Bio-Path Holdings Reports First Quarter 2024 Financial ResultsNASDAQ:BPTHBio Path Holdings Inc
05/14/20243:10PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BPTHBio Path Holdings Inc
05/08/20246:00AMGlobeNewswire Inc.Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024NASDAQ:BPTHBio Path Holdings Inc
04/19/202411:14AMGlobeNewswire Inc.Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:BPTHBio Path Holdings Inc
04/18/202412:57PMGlobeNewswire Inc.Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:BPTHBio Path Holdings Inc
04/18/20246:00AMGlobeNewswire Inc.Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) PatientsNASDAQ:BPTHBio Path Holdings Inc
04/15/20246:00AMGlobeNewswire Inc.Bio-Path Holdings Expands Global Patent PortfolioNASDAQ:BPTHBio Path Holdings Inc
04/02/20246:00AMGlobeNewswire Inc.Bio-Path Holdings Provides 2024 Clinical and Operational UpdateNASDAQ:BPTHBio Path Holdings Inc
03/11/20246:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BPTHBio Path Holdings Inc
03/08/20244:11PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:BPTHBio Path Holdings Inc
03/08/20246:10AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BPTHBio Path Holdings Inc
03/08/20246:00AMGlobeNewswire Inc.Bio-Path Holdings Reports Full Year 2023 Financial ResultsNASDAQ:BPTHBio Path Holdings Inc
03/08/20245:22AMIH Market NewsU.S. Index Futures Fluctuate Ahead of Key Jobs Report; Oil Prices DipNASDAQ:BPTHBio Path Holdings Inc
03/07/20243:21PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BPTHBio Path Holdings Inc
03/01/20246:00AMGlobeNewswire Inc.Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024NASDAQ:BPTHBio Path Holdings Inc
02/29/20245:00AMEdgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:BPTHBio Path Holdings Inc
02/23/20246:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BPTHBio Path Holdings Inc
02/21/20246:00AMGlobeNewswire Inc.Bio-Path Holdings Announces 1-for-20 Reverse Stock SplitNASDAQ:BPTHBio Path Holdings Inc
02/02/20243:39PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:BPTHBio Path Holdings Inc
02/02/20243:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BPTHBio Path Holdings Inc
01/23/20244:20PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BPTHBio Path Holdings Inc
01/23/20243:51PMEdgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:BPTHBio Path Holdings Inc
01/17/20243:52PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:BPTHBio Path Holdings Inc
01/10/20243:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BPTHBio Path Holdings Inc
01/10/20246:00AMGlobeNewswire Inc.Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia PatientsNASDAQ:BPTHBio Path Holdings Inc
01/04/20244:18PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:BPTHBio Path Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:BPTH